- Astria TherapeuticS press release ( NASDAQ: ATXS ): Q3 GAAP EPS of -$0.87 beats by $0.05 .
- Cash Position: As of September 30, 2022, Astria had cash, cash equivalents and short-term investments of $116.6 million, compared to $131.8 million as of September 30, 2021.
- Capital Structure: As of November 3, 2022, there were 17,051,429 shares of common stock issued and outstanding.
-
Loss from operations was $12.4 million for the three months ended September 30, 2022, compared to $7.9 million for the three months ended September 30, 2021.
-
Net Loss: Net loss was $12.0 million for the three months ended September 30, 2022, compared to a net loss of $7.9 million for the three months ended September 30, 2021.
For further details see:
Astria TherapeuticS GAAP EPS of -$0.87 beats by $0.05